Abstract
Histone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are validated drug targets for some types of cancer and are promising therapeutic targets for a range of other diseases, including malaria. Annually, there are ~500 million clinical cases of malaria and ~0.8-1.2 million deaths. There is no licensed vaccine for preventing malaria, and parasites that cause malaria are becoming resistant to current drugs, necessitating the search for new therapies. HDAC inhibitors are emerging as a promising new class of antimalarial drugs with potent and selective action against Plasmodium parasites in vitro. Recent studies on the effects of HDAC inhibitors on the growth and development of P. falciparum have provided important new information on transcriptional regulation in malaria parasites and have validated the potential of this class of inhibitors for malaria therapy. To realise effective HDAC inhibitors for clinical trials, next generation inhibitors must not inhibit other human HDACs or proteins required for normal human physiology, be highly selective in killing parasites in vivo without killing normal host cells, and have improved bioavailability and pharmacokinetic profiles. This review summarizes current knowledge about malaria parasite HDACs and HDAC inhibitors with antimalarial properties, and provides insights for their development into new drugs for treatment of malaria.
Keywords: Histone deacetylase, HDAC inhibitor, malaria, Plasmodium falciparum, antimalarial drugs, post-translational modifications, epigenetic changes, vaccine, bioavailability, pharmacokinetic profiles
Current Pharmaceutical Design
Title:Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs
Volume: 18 Issue: 24
Author(s): Katherine T. Andrews, Thanh N. Tran and David P. Fairlie
Affiliation:
Keywords: Histone deacetylase, HDAC inhibitor, malaria, Plasmodium falciparum, antimalarial drugs, post-translational modifications, epigenetic changes, vaccine, bioavailability, pharmacokinetic profiles
Abstract: Histone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are validated drug targets for some types of cancer and are promising therapeutic targets for a range of other diseases, including malaria. Annually, there are ~500 million clinical cases of malaria and ~0.8-1.2 million deaths. There is no licensed vaccine for preventing malaria, and parasites that cause malaria are becoming resistant to current drugs, necessitating the search for new therapies. HDAC inhibitors are emerging as a promising new class of antimalarial drugs with potent and selective action against Plasmodium parasites in vitro. Recent studies on the effects of HDAC inhibitors on the growth and development of P. falciparum have provided important new information on transcriptional regulation in malaria parasites and have validated the potential of this class of inhibitors for malaria therapy. To realise effective HDAC inhibitors for clinical trials, next generation inhibitors must not inhibit other human HDACs or proteins required for normal human physiology, be highly selective in killing parasites in vivo without killing normal host cells, and have improved bioavailability and pharmacokinetic profiles. This review summarizes current knowledge about malaria parasite HDACs and HDAC inhibitors with antimalarial properties, and provides insights for their development into new drugs for treatment of malaria.
Export Options
About this article
Cite this article as:
T. Andrews Katherine, N. Tran Thanh and P. Fairlie David, Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs, Current Pharmaceutical Design 2012; 18 (24) . https://dx.doi.org/10.2174/138161212801327257
DOI https://dx.doi.org/10.2174/138161212801327257 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Atherosclerosis The Implications of Being a Woman
Current Hypertension Reviews Resveratrol and Cardiovascular Disease
Current Nutrition & Food Science Invasive aspergillosis: adjunctive combination therapy
Mini-Reviews in Medicinal Chemistry Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Advances in Nutritional Metabolomics
Current Metabolomics Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Structure Prediction of LDLR-HNP1 Complex Based on Docking Enhanced by LDLR Binding 3D Motif
Protein & Peptide Letters Oxidative Stress and Psychological Disorders
Current Neuropharmacology Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Biomarkers in Unstable Carotid Plaque: Physiopathology and Prediction
Cardiovascular & Hematological Agents in Medicinal Chemistry Catalytic DNA: A Novel Tool for Gene Suppression
Current Drug Targets Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Current Neuropharmacology Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review
Mini-Reviews in Medicinal Chemistry